T. Spelman Et Al. , "Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom," JOURNAL OF MEDICAL ECONOMICS , vol.27, no.1, pp.109-125, 2024
Spelman, T. Et Al. 2024. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. JOURNAL OF MEDICAL ECONOMICS , vol.27, no.1 , 109-125.
Spelman, T., Herring, W. L., Acosta, C., Hyde, R., Jokubaitis, V. G., Pucci, E., ... Lugaresi, A.(2024). Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. JOURNAL OF MEDICAL ECONOMICS , vol.27, no.1, 109-125.
Spelman, T. Et Al. "Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom," JOURNAL OF MEDICAL ECONOMICS , vol.27, no.1, 109-125, 2024
Spelman, T. Et Al. "Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom." JOURNAL OF MEDICAL ECONOMICS , vol.27, no.1, pp.109-125, 2024
Spelman, T. Et Al. (2024) . "Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom." JOURNAL OF MEDICAL ECONOMICS , vol.27, no.1, pp.109-125.
@article{article, author={T. Spelman Et Al. }, title={Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom}, journal={JOURNAL OF MEDICAL ECONOMICS}, year=2024, pages={109-125} }